- Home
- Â /Â Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Stock Price
$927.3
2024-10-29
Market Capitalization
$102.2 B
2024-10-29
Revenue
$14.3 B
FY, 2025
Regeneron Pharmaceuticals Summary
Company Summary
- Overview
- Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines. It offers products for the treatment of eye diseases, allergic and inflammatory conditions, infectious diseases, cardiovascular and metabolic disorders, pain, cancer, and hematologic conditions, etc.
- Type
- Public
- Status
- Active
- Founded
- 1988
- HQ
- Tarrytown, NY, US | view all locations
- Website
- https://www.regeneron.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
George D. Yancopoulos, Board Co-Chair, President and Chief Scientific Officer, Founder
Bob McCowan, Senior Vice President, IT and Chief Information Officer
Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer
Operating MetricsView all
Product Candidates
35
2.8%
FY, 2022
Cell Culture Capacity, liters
220K
4.3%
FY, 2022
Products
11
10.0%
FY, 2022
LocationsView all
20 locations detected
Tarrytown, NYÂ HQ
United States
777 Old Saw Mill River Rd
Armonk, NY
United States
175 King St
Bernards, NJ
United States
110 Allen Rd, Basking Ridge
Cambridge, MA
United States
60 Binney St
Rensselaer, NY
United States
81 Columbia Turnpike
Seattle, WA
United States
188 E Blaine St #300
Regeneron Pharmaceuticals Financials
Summary Financials
- Revenue (Q1, 2026)
- $3.6B
- Net income (Q1, 2026)
- $727.2M
- Cash (Q1, 2026)
- $3.0B
- EBIT (Q1, 2026)
- $642.9M
- Enterprise value
- $101.2B